Clinical response and serum gold levels in chrysotherapy. Lack of correlation
about
Gold binding to blood cells and serum proteins during chrysotherapy.Blood gold concentrations in children with juvenile rheumatoid arthritis undergoing long-term oral gold therapy.Free thiomalate levels in patients with rheumatoid arthritis treated with disodium aurothiomalate: relationship to clinical outcome of therapyAuranofin. New oral gold compound for treatment of rheumatoid arthritis.Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C.Inhibition of human endothelial cell proliferation by gold compounds.Gold serum levels in children with juvenile rheumatoid arthritis.Distribution of gold among plasma fractions in rheumatoid patients undergoing chrysotherapy compared with its distribution in plasma incubated with aurothiomalate in vitro.Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis.Inhibition of antigen- and mitogen-induced human lymphocyte proliferation by gold compounds.Gold in erythrocytes, whole blood, and plasma during long-term chrysotherapyBinding of sodium aurothiomalate to human serum albumin in vitro at physiological conditions.Use of yttrium 90 in persistent synovitis of the knee. I. Retention in the knee and spread in the body after injection.Serum gold determinations in patients with rheumatoid arthritis receiving sodium aurothiomalate.Tissue gold levels after chrysotherapy.Aurothiomalate inhibits the expression of mPGES-1 in primary human chondrocytes.Aurothiomalate and hydroxychloroquine inhibit nitric oxide production in chondrocytes and in human osteoarthritic cartilage.Gold and Female Reproductive Organs: an Ultrastructural Study.
P2860
Q33552310-AB3F86EF-19C9-4F38-9136-14FC78FF2233Q33555294-5A724F7C-48B3-4FCC-9A76-9CB7B61BE23FQ33555432-29956FCE-8905-4EE5-9ECF-A221CCE5A753Q33569714-D60B3862-5F5C-40CB-904C-506FA6C04FB8Q34220395-5FA6B320-6224-4669-AB72-751D18EAAADFQ34572131-D5CE5BC1-2286-41E4-B98E-FDF963E0C27BQ39636845-8AA4AC38-3C37-4D43-AF1E-E682FB84B291Q39692411-21376736-CD8C-470A-9C56-C48E7747BB65Q40209857-03AFD263-C34A-48D7-89C8-BB93C94D2D95Q40529854-01F92E22-8B4C-4419-BB3C-1399354B2A27Q41124481-262D35C6-124E-4422-9C7A-E3AE6D12BD33Q41155539-62CE9C0B-48B5-4E9D-B647-1A98744FDF13Q41312675-3747E210-0FDC-4123-80AB-33DFCEB22F61Q41312742-0AAF0E83-18C7-42FD-8276-59B6C14B0208Q41326096-B9937FF2-5D88-4710-A9FE-40F4FB44EB65Q41919879-DCB8C008-28DA-4538-86DE-6F9F408D472FQ41946134-5B716AEF-A88A-4752-86BF-BA27BF54B739Q47659549-E236F4A1-DA86-4FFC-9542-089A6D17E658
P2860
Clinical response and serum gold levels in chrysotherapy. Lack of correlation
description
1972 nî lūn-bûn
@nan
1972 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1972 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1972年の論文
@ja
1972年論文
@yue
1972年論文
@zh-hant
1972年論文
@zh-hk
1972年論文
@zh-mo
1972年論文
@zh-tw
1972年论文
@wuu
name
Clinical response and serum gold levels in chrysotherapy. Lack of correlation
@ast
Clinical response and serum gold levels in chrysotherapy. Lack of correlation
@en
Clinical response and serum gold levels in chrysotherapy. Lack of correlation.
@nl
type
label
Clinical response and serum gold levels in chrysotherapy. Lack of correlation
@ast
Clinical response and serum gold levels in chrysotherapy. Lack of correlation
@en
Clinical response and serum gold levels in chrysotherapy. Lack of correlation.
@nl
prefLabel
Clinical response and serum gold levels in chrysotherapy. Lack of correlation
@ast
Clinical response and serum gold levels in chrysotherapy. Lack of correlation
@en
Clinical response and serum gold levels in chrysotherapy. Lack of correlation.
@nl
P2093
P2860
P356
P1476
Clinical response and serum gold levels in chrysotherapy. Lack of correlation
@en
P2093
Bluestone R
Pearson CM
P2860
P304
P356
10.1136/ARD.31.4.308
P407
P577
1972-07-01T00:00:00Z